Abstract #0225

Diagnostic performance of an abbreviated gadoxetic acid enhanced-MRI (AMRI) vs. ultrasound for detection of small HCC: pilot study.

Cecilia Besa¹, Sara Lewis¹, Mathilde Wagner^1,2, Yujin Hoshida³, Ruth Carlos⁴, Claude B Sirlin⁵, and Bachir Taouli¹

¹Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States, ²Radiology, Groupe Hospitalier Pitié Salpêtrière, Paris, France, ³Department of Medicine/Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, United States, ⁴Radiology, Division of Abdominal Radiology, University of Michigan Health System, Ann Arbor, MI, United States, ⁵Liver Imaging Group, Department of Radiology, University of California, San Diego, CA, United States

In this study, we aim to test the diagnostic value of an abbreviated MRI (AMRI) using gadoxetic acid (with patient injected outside the MRI room) compared to ultrasound (US) for hepatocellular carcinoma (HCC) detection in a population of patients with small HCC and controls. This study demonstrates that AMRI using T1WI obtained at the hepatobiliary phase (T1w-HBP), diffusion weighted imaging (DWI) and T2WI has superior diagnostic performance for HCC detection compared to US. This could serve as the basis for a future study assessing AMRI for HCC screening/surveillance in patients with cirrhosis.

This abstract and the presentation materials are available to members only; a login is required.

Join Here